PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
ID: 355265Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355265

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-24-245.html
Timeline
    Description

    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications. This funding opportunity invites eligible U.S. small businesses to propose innovative projects that demonstrate significant commercialization potential, specifically excluding clinical trials. The grants aim to support research and development aligned with the missions of the NIH, CDC, and FDA, with funding amounts typically reaching up to $306,872 for Phase I and $2,045,816 for Phase II awards. Interested applicants must submit their proposals by April 5, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-245.html for further details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-24-245-Full-Announcement.html
    PA-24-245.html
    The Department of Health and Human Services has released a Notice of Funding Opportunity (NOFO) inviting U.S. small businesses to apply for Small Business Innovation Research (SBIR) grants from the NIH, CDC, and FDA. This opportunity allows companies to propose projects that have significant commercialization potential without involving clinical trials. The announcement details the participation of various NIH components and CDC centers, with funding available under several SBIR phases—Phase I, Phase II, Fast-Track, and Direct to Phase II. Eligible small businesses must comply with specified criteria, including being U.S.-based and primarily owned by U.S. citizens. The NOFO outlines application submission requirements, including the necessity for various registrations and adherence to strict application guidelines. Funding amounts generally do not exceed $306,872 for Phase I and $2,045,816 for Phase II awards, with project periods not exceeding 6 months and 2 years, respectively. Applicants are encouraged to develop a strong commercialization plan, reflecting the potential to bring innovative solutions to market, thereby advancing the health technologies aligned with the missions of the NIH, CDC, and FDA.
    Similar Opportunities
    PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications, specifically requiring clinical trials. This funding opportunity is aimed at U.S. small businesses with the necessary research capabilities to contribute to the missions of the NIH and CDC, encouraging innovation and the commercial viability of health technologies. Eligible applicants can receive funding up to $306,872 for Phase I and $2,045,816 for Phase II, with a submission deadline of April 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) to support pre-clinical research aimed at bridging funding gaps that impede the commercialization of medical biotechnology products. This funding opportunity specifically targets previously funded SBIR or STTR Phase II projects, with the objective of advancing products or technologies that require federal regulatory approval, while fostering partnerships between small businesses and external investors to enhance commercialization prospects. Applicants are encouraged to secure independent third-party funding that equals or exceeds one-third of the requested NINDS funds, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in the research environment. The application deadline is April 5, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html.
    SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "SBIR Solutions to Enable Population Genomic Screening," aimed at soliciting Small Business Innovation Research (SBIR) grant applications from U.S. small businesses. The objective of this initiative is to develop innovative solutions that facilitate population genomic screening for common, actionable genomic conditions within primary care settings, addressing significant barriers such as logistical challenges, provider education, and follow-up procedures. This program is crucial for enhancing the readiness of primary care providers to manage genomic screening, particularly for conditions like hereditary breast cancer and Lynch syndrome. Grants of up to $400,000 are available for Phase I applications, with Phase II grants potentially reaching $2.15 million. Interested applicants should note that the submission window opens on November 1, 2024, with a deadline for applications set for December 2, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering NINDS Renewal Awards of Small Business Innovation Research (SBIR) Phase II Grants (Phase IIB) to support clinical trials and clinical research projects focused on neurological disorders. This funding opportunity encourages small business concerns (SBCs) to seek additional funding for projects previously funded by NIH SBIR and STTR Phase II awards, with an emphasis on facilitating the transition of these projects to commercialization through partnerships with third-party investors. The initiative aims to address the "Valley of Death" funding gap in medical biotechnology, particularly for products related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants must submit a Commercialization Plan and a Plan for Enhancing Diverse Perspectives (PEDP), with the application opening on August 5, 2024, and a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, which aims to support small business concerns (SBCs) in advancing their previously funded SBIR and STTR Phase II and Phase IIB projects towards commercialization. This funding opportunity provides financial assistance for technical support and late-stage research and development activities that are typically not covered by standard Phase II or Phase IIB grants, excluding clinical trials. Eligible applicants must have active Phase II or Phase IIB awards from participating NIH institutes within the last 36 months, with potential funding reaching up to $1,000,000 per year for a maximum of three years. Interested parties should contact NIH Grants Information at grantsinfo@nih.gov for further inquiries, and note that the application deadline is April 5, 2025.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.